#USA #Stockholm #Olezarsen #Sobi® #Tryngolza®

New Breakthrough Analysis: Tryngolza® in the Fight Against Acute Pancreatitis

In a remarkable development in the fight against severe hypertriglyceridemia (sHTG), a new analysis has revealed that Tryngolza® (olezarsen) markedly reduces the occurrence of acute pancreatitis by 85%. This monumental finding is based on pooled data from the Phase 3 CORE and CORE2 clinical trials, underscoring the drug's potential impact on a chronic and challenging condition.

The analysis, which was shared at the recent European Atherosclerosis Society (EAS) Congress in Athens, Greece, evaluated the effects of Tryngolza on 455 patients diagnosed with severe hypertriglyceridemia, defined by triglyceride levels of at least 880 mg/dL (or approximately 10 mmol/L). Over six months, those treated with Tryngolza at a dosage of 80 mg demonstrated a significant 66% reduction in triglyceride levels compared to a placebo, while those on a 50 mg dosage experienced a 59% decrease. Impressively, 85% of the patients receiving the higher dose achieved triglyceride levels considered safe (<10 mmol/L).

Dr. Børge Nordestgaard, a leading researcher from Copenhagen University Hospital, highlighted the urgent need for effective treatments, citing that individuals with triglyceride levels exceeding 10 mmol/L experience a quadrupled risk of acute pancreatitis. The study's results indicate that the treatment not only mitigates the immediate risks but also moves patients toward safer triglyceride levels—an essential measure in preventing dire health outcomes.

Acute pancreatitis is known for its debilitating symptoms and is often a medical emergency. With its incidence rising steadily, Sobi's findings are crucial amidst an increasing burden on healthcare systems worldwide. Acute pancreatitis has seen an annual increase of approximately 3% since the 1960s, contributing to heightened healthcare demands. With severe hypertriglyceridemia being the third leading cause of this life-threatening condition, the introduction of effective treatment options like Tryngolza offers hope in managing both the condition and its serious complications.

As per further insights shared by Dr. Lydia Abad-Franch, Chief Medical Officer at Sobi, the implications of these findings could be profound as they point toward a significant advancement in preventive care for at-risk populations. The analysis demonstrated not only a decrease in pancreatitis risk but also a reduction in cholesterol levels, providing a multi-faceted approach to managing severe hypertriglyceridemia.

The CORE and CORE2 studies, which formed the basis for this analysis, evidenced the drug's efficacy through a rigorous placebo-controlled trial framework. Patients were subjected to subcutaneous injections of olezarsen every four weeks over a 12-month period. With results indicating that just nine patients would need to be treated for one to avoid an episode of acute pancreatitis, the findings are viewed favorably by healthcare professionals looking to mitigate risks associated with high triglycerides.

With the European Medicines Agency granting an extension application for olezarsen's use and the U.S. FDA prioritizing its review, the pathway for Tryngolza as a mainstream therapeutic option appears promising. Developed in partnership with Ionis Pharmaceuticals, Sobi has ensured exclusivity of the medication’s commercialization, making this treatment accessible to patients across various regions, except for Canada and China.

In summation, the results from the new analysis bolster the narrative around olezarsen’s role in combatting severe hypertriglyceridemia and its association with acute pancreatitis. As healthcare providers await further regulatory confirmations, the clinical community remains optimistic about others embracing this innovative treatment in preventive care routines. Through clinical advancements like these, patients may find renewed hope and a more profound sense of security in managing their health effectively.

This investigation not only illustrates the potential of olezarsen in clinical settings but also emphasizes the continuous need for diligent research and development in tackling complex medical conditions that plague society today.